Is Arcturus Therapeutics Holdings, Inc. overvalued or undervalued?

As of 7 March 2024, the valuation grade for Arcturus Therapeutics Holdings, Inc. has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company is currently assessed as overvalued given its negative earnings performance and troubling financial ratios. Key metrics include a Price to Book Value of 1.48, an EV to EBITDA of -3.10, and a Return on Equity (ROE) of -5.41%.
In comparison to its peers, Arcturus Therapeutics shows a stark contrast with Innoviva, Inc., which has a P/E ratio of 15.38, and Collegium Pharmaceutical, Inc., with a fair valuation and a P/E of 14.78. The negative returns of Arcturus, particularly a staggering -54.43% over the past year compared to the S&P 500's 10.26%, further emphasize its overvaluation in the current market landscape.